| Alector is a clinical stage biopharmaceutical company. Co. is engaged in developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. Co.'s preclinical and clinical programs include: AL001, which is Co.'s progranulin (PGRN) product candidate in clinical development, is designed to treat frontotemporal dementia, a severe, rapidly progressing neurodegenerative disorder: AL101, which is Co.'s second PGRN product candidate that is being developed for the indications, such as Alzheimer's disease and Parkinson's disease; and AL002 and AL003, which are candidate for Alzheimer's disease. We show 4 historical shares outstanding datapoints in our ALEC shares outstanding history coverage, used to compute ALEC market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALEC market cap history over the course of time is important for investors
interested in comparing ALEC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALEC versus a peer is one thing; comparing
ALEC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALEC can fluctuate over the course of history.
With this page we aim to empower investors researching ALEC by allowing them to research the ALEC market cap history.